540 related articles for article (PubMed ID: 17191775)
1. Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present, and future.
De Clercq E
Chem Biodivers; 2004 Jan; 1(1):44-64. PubMed ID: 17191775
[TBL] [Abstract][Full Text] [Related]
2. [Non-nucleoside reverse transcriptase inhibitors].
Joly V; Yeni P
Ann Med Interne (Paris); 2000 Jun; 151(4):260-7. PubMed ID: 10922953
[TBL] [Abstract][Full Text] [Related]
3. HIV-reverse transcriptase inhibition: inclusion of ligand-induced fit by cross-docking studies.
Ragno R; Frasca S; Manetti F; Brizzi A; Massa S
J Med Chem; 2005 Jan; 48(1):200-12. PubMed ID: 15634014
[TBL] [Abstract][Full Text] [Related]
4. Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase.
Ren J; Stammers DK
Virus Res; 2008 Jun; 134(1-2):157-70. PubMed ID: 18313784
[TBL] [Abstract][Full Text] [Related]
5. New anti-HIV agents and targets.
De Clercq E
Med Res Rev; 2002 Nov; 22(6):531-65. PubMed ID: 12369088
[TBL] [Abstract][Full Text] [Related]
6. The effect of NNRTIs on HIV reverse transcriptase dimerization.
Tachedjian G; Goff SP
Curr Opin Investig Drugs; 2003 Aug; 4(8):966-73. PubMed ID: 14508881
[TBL] [Abstract][Full Text] [Related]
7. Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection.
De Clercq E
Farmaco; 1999; 54(1-2):26-45. PubMed ID: 10321027
[TBL] [Abstract][Full Text] [Related]
8. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection.
De Clercq E
Antiviral Res; 1998 Jun; 38(3):153-79. PubMed ID: 9754886
[TBL] [Abstract][Full Text] [Related]
9. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
Ambrose Z; Boltz V; Palmer S; Coffin JM; Hughes SH; Kewalramani VN
J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466
[TBL] [Abstract][Full Text] [Related]
10. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009).
de Béthune MP
Antiviral Res; 2010 Jan; 85(1):75-90. PubMed ID: 19781578
[TBL] [Abstract][Full Text] [Related]
11. Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.
Balzarini J
Curr Top Med Chem; 2004; 4(9):921-44. PubMed ID: 15134549
[TBL] [Abstract][Full Text] [Related]
12. A single conservative amino acid substitution in the reverse transcriptase of human immunodeficiency virus-1 confers resistance to (+)-(5S)-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo[4,5, 1- jk][1,4]benzodiazepin-2(1H)-thione (TIBO R82150).
Mellors JW; Im GJ; Tramontano E; Winkler SR; Medina DJ; Dutschman GE; Bazmi HZ; Piras G; Gonzalez CJ; Cheng YC
Mol Pharmacol; 1993 Jan; 43(1):11-6. PubMed ID: 7678690
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 reverse transcriptase inhibitors.
El Safadi Y; Vivet-Boudou V; Marquet R
Appl Microbiol Biotechnol; 2007 Jun; 75(4):723-37. PubMed ID: 17370068
[TBL] [Abstract][Full Text] [Related]
14. Kinetics of different human immunodeficiency virus type 1 reverse transcriptases resistant to human immunodeficiency virus type 1-specific reverse transcriptase inhibitors.
Debyser Z; De Vreese K; Knops-Gerrits PP; Baekelandt V; Bhikhabhai R; Strandberg B; Pauwels R; Anné J; Desmyter J; De Clercq E
Mol Pharmacol; 1993 Apr; 43(4):521-6. PubMed ID: 7682649
[TBL] [Abstract][Full Text] [Related]
15. Substrate-dependent inhibition or stimulation of HIV RNase H activity by non-nucleoside reverse transcriptase inhibitors (NNRTIs).
Hang JQ; Li Y; Yang Y; Cammack N; Mirzadegan T; Klumpp K
Biochem Biophys Res Commun; 2007 Jan; 352(2):341-50. PubMed ID: 17113568
[TBL] [Abstract][Full Text] [Related]
16. Novel HIV-1 reverse transcriptase inhibitors.
Jochmans D
Virus Res; 2008 Jun; 134(1-2):171-85. PubMed ID: 18308412
[TBL] [Abstract][Full Text] [Related]
17. Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors.
Tambuyzer L; Azijn H; Rimsky LT; Vingerhoets J; Lecocq P; Kraus G; Picchio G; de Béthune MP
Antivir Ther; 2009; 14(1):103-9. PubMed ID: 19320243
[TBL] [Abstract][Full Text] [Related]
18. Susceptibility of feline immunodeficiency virus/human immunodeficiency virus type 1 reverse transcriptase chimeras to non-nucleoside RT inhibitors.
Auwerx J; Esnouf R; De Clercq E; Balzarini J
Mol Pharmacol; 2004 Jan; 65(1):244-51. PubMed ID: 14722257
[TBL] [Abstract][Full Text] [Related]
19. Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors.
Ren J; Nichols C; Bird L; Chamberlain P; Weaver K; Short S; Stuart DI; Stammers DK
J Mol Biol; 2001 Sep; 312(4):795-805. PubMed ID: 11575933
[TBL] [Abstract][Full Text] [Related]
20. Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors.
Das K; Lewi PJ; Hughes SH; Arnold E
Prog Biophys Mol Biol; 2005 Jun; 88(2):209-31. PubMed ID: 15572156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]